Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in ...
3 days ago · Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update Alector, Inc. Mon, Nov 25, 2024, 4:05 PM 5 min read
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II ...
2 days ago · Alector on Monday announced that its investigational antibody AL002 failed the Phase II INVOKE-2 study, as it did not significantly slow clinical progression in patients with Alzheimer’s disease.. Data were sparse in the press announcement, with the biotech only revealing that AL002 “failed to meet the primary efficacy endpoint,” which was measured using the Clinical Dementia Rating Sum ...
Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
2 days ago · Across both AL002 and AL003, the deal was worth up to $985.6 million in option exercise and milestone payments, with only paydays tied to AL002 remaining after the AL003 portion was axed.
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
3 days ago · Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update. November 25, 2024 16:05 ET | Source: ...
Alector stock drops after Alzheimer’s drug fails in Phase II trial
2 days ago · Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to meet the primary endpoint. The therapy failed to slow ...
AL002 Falls Short in Phase 2 INVOKE-2 Trial of Early Alzheimer …
2 days ago · In a company update, Alector announced that its investigational agent AL002, a TREM2-targeting therapy, did not meet any of its primary, secondary, or exploratory end points in the phase 2 INVOKE-2 trial (NCT04592874) of patients with early-stage Alzheimer disease (AD).
Alector Therapeutics’ novel Alzheimer’s strategy fails in ... - STAT
2 days ago · In the 381-person trial, however, patients who received AL002 didn’t decline more slowly than patients who were on placebo, as measured by a scale called the Clinical Dementia Rating Sum of Boxes.
Alector turns to layoffs as Alzheimer’s drug fails
2 days ago · Alector recorded a net loss of $42 million during the third quarter. AL002 is an antibody drug designed to activate a protein found on the surface of certain cells made in the bone marrow. Studies suggests this “TREM2” protein performs a variety of important functions, with one being the promotion of immune cells that reside in the brain.
Alector Plummets After Alzheimer's Drug Trial Fails
2 days ago · Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
1 day ago · US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). However, AL002 failed to meet the primary endpoint of slowing of Alzheimer’s clinical ...
- Some results have been removed